1. Buyer: Amgen
Target: Onyx
Price: $10.4 billion

As analysts put it before the Onyx buyout, the California-based company was one of just a handful of smaller drugmakers with enough revenue and revenue potential to "move the needle" for big biopharma companies. So when Amgen ($AMGN) first came calling last summer with a $10 billion bid, Onyx spurned it to hold out for a better offer.

Amgen did ultimately prevail, with Onyx's price reportedly scaring off would-be buyers like Pfizer ($PFE). Amgen CEO Robert Bradway haggled down the cost somewhat by requesting interim trial data he knew Onyx couldn't reveal; when the company refused to unblind its Phase III study, he used it as grounds to pare down his next bid. Not long after, the two sides reached a deal somewhere in the middle.

At the center of that deal was Kyprolis, the hot-selling blood cancer med that scored $64 million between its July 2012 launch and the end of that year--despite competition from Celgene's ($CELG) Revlimid and Johnson & Johnson's ($JNJ) Velcade. With four studies to support and extend Kyprolis' market position ongoing, analysts have predicted the multiple myeloma drug will generate $2.4 billion in 2019, with some thinking it will reach as high as $3 billion at its peak.

Whatever Kyprolis does churn out will take the pressure off Amgen's older meds, some of which--like anemia drug Epogen--now face biosimilar competition.

For more:
Special Reports: Top 15 Drug Launch Superstars - Kyprolis | Top 20 orphan drugs by 2018 - Kyprolis
Amgen CEO scored Onyx with unorthodox M&A move
Amgen nabs Onyx for $10.4B. What's next for Kyprolis?
Onyx hands bidders new Kyprolis data to smooth path to $9.5B deal
Onyx CEO dismisses rumors that Amgen alone is still in the hunt
Report: Pfizer backs off Onyx bid as price gets too rich
Onyx puts out 'for sale' sign after rejecting $10B Amgen bid

-- Carly Helfand (email | Twitter)


Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.